Jeffrey Lieberman, MD, is Chair of Psychiatry at Columbia University College of Physicians and Surgeons and past president of the American Psychiatric Association. Dr. Lieberman is a nationally renowned psychiatrist on the topic of suicide, addiction and mental illness and is a regular blogger for The Huffington Post, Forbes, U.S. News & World Report and Psychology Today and author of “Shrinks: The Untold Story of Psychiatry.” www.jeffreyliebermanmd.com
Episodes
Wednesday Sep 29, 2021
Wednesday Sep 29, 2021
In this episode, Dr. Jeffrey Lieberman is joined by pioneering psychedelics researchers, Drs. Rick Doblin and Steven Levine, to discuss the therapeutic applications of psychedelic drugs such as psilocybin, ketamine, LSD, MDMA, and ibogaine in treating mental health and addiction disorders, and the future path forward in legitimately harnessing their game changing potential.
Dr. Rick Doblin is the Founder and Executive Director of MAPS (the Multidisciplinary Association for Psychedelic Studies), , a leading non-profit psychedelic drugs research and educational organization, with both domestic and international studies.
Dr. Steven Levine is the Vice President of Patient Access at COMPASS Pathways, a leading psychedelics research organization conducting international clinical trials with psilocybin therapy for treatment-resistant depression. A pioneer in the clinical use of IV ketamine for treatment resistant depression, Dr. Levine is also the founder of Actify Neurotherapies, one of the largest networks of ketamine treatment centers in the US.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.